T. Rowe Price Associates
IRMD icon

T. Rowe Price Associates’s iRadimed IRMD Stock Holding History

T. Rowe Price Associates’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$596K Buy
6,184
+1,402
+29% +$140K ﹤0.01% 2370
2025
Q4 		$466K Buy
4,782
+458
+11% +$39.3K ﹤0.01% 2430
2025
Q3 		$308K Buy
4,324
+476
+12% +$31.7K ﹤0.01% 2593
2025
Q2 		$231K Buy
+3,848
New +$211K ﹤0.01% 2650

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's IRMD Position: Q1 2026 in Review

T. Rowe Price Associates increased its iRadimed (IRMD) stake by 29% in Q1 2026, buying an estimated $140K and bringing the position to 6,184 shares worth $596K. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

T. Rowe Price Associates first reported a position in IRMD in Q2 2025 and has held it in 4 quarters since. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • T. Rowe Price Associates held 6,184 shares of iRadimed worth $596K as of Q1 2026.
  • T. Rowe Price Associates bought 1,402 iRadimed shares in Q1 2026, an estimated $140K.
  • iRadimed made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2370 holding.
  • T. Rowe Price Associates first reported a position in iRadimed in Q2 2025 and has held it in 4 quarters since.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.